Table 1.
Demographic, clinical, and therapeutic characteristics of patients
| Baseline normal LVEF group (N = 572) |
Recovered LVEF group (N = 254) |
Persistently reduced LVEF group (N = 299) |
P value | |
|---|---|---|---|---|
| Age, years | 61.7 ± 11.3 | 63.6 ± 11.5 | 64.8 ± 11.2 | < 0.001 |
| Male | 478 (83.6%) | 206 (81.1%) | 252 (84.3%) | 0.576 |
| BMI, kg/m2 | 24.5 (22.6–26.6) | 24.3 (22.8–26.1) | 24.4 (22.8–26.6) | 0.895 |
| Hypertension | 343 (60.0%) | 158 (62.2%) | 187 (62.5%) | 0.704 |
| Diabetes | 181 (31.6%) | 90 (35.4%) | 123 (41.1%) | 0.020 |
| Chronic kidney disease | 37 (6.5%) | 9 (3.5%) | 18 (6.0%) | 0.236 |
| Prior stroke | 45 (7.9%) | 17 (6.7%) | 24 (8.0%) | 0.807 |
| Prior PCI | 29 (5.1%) | 6 (2.4%) | 8 (2.7%) | 0.084 |
| Smoking | 358 (62.6%) | 154 (60.6%) | 180 (60.2%) | 0.748 |
| Anterior MI | 192 (33.6%) | 142 (55.9%) | 232 (77.6%) | < 0.001 |
| Killip class II–IV | 57 (10.0%) | 34 (13.4%) | 53 (17.7%) | 0.005 |
| SBP, mmHg | 133.9 ± 23.2 | 136.3 ± 24.5 | 137.2 ± 26.2 | 0.132 |
| Heart rate, beats/min | 75.7 ± 15.1 | 79.7 ± 20.0 | 85.8 ± 18.7 | < 0.001 |
| Out-of-hospital cardiac arrest | 16 (2.8%) | 12 (4.7%) | 7 (2.3%) | 0.227 |
| Multivessel disease | 311 (54.4%) | 153 (60.2%) | 172 (57.7%) | 0.262 |
| TIMI flow 0–1 before PCI | 330 (57.7%) | 168 (66.1%) | 217 (72.6%) | < 0.001 |
| Usage of IABP | 7 (1.2%) | 20 (7.9%) | 33 (11.0%) | < 0.001 |
| Baseline LVEF, % | 57.0 (53.0–60.0) | 43.0 (40.0–48.0) | 38.0 (34.0–43.0) | < 0.001 |
| Initial creatinine, umol/L | 77.2 (66.7–89.2) | 78.4 (65.9–90.2) | 79.8 (67.8–97.1) | 0.028 |
| Peak troponin T, ng/mL | 4.56 (2.04–8.53) | 5.76 (3.00–9.93) | 10.00 (5.21–10.00) | < 0.001 |
| Medication at discharge | ||||
| Aspirin | 542 (94.8%) | 248 (97.6%) | 284 (95.0%) | 0.166 |
| Anti-P2Y12 receptors | 553 (96.7%) | 251 (98.8%) | 295 (98.7%) | 0.071 |
| Statins | 549 (96.0%) | 245 (96.5%) | 292 (97.7%) | 0.436 |
| ACEIs/ARBs | 319 (55.8%) | 158 (62.2%) | 172 (57.5%) | 0.224 |
| β-receptor blockers | 403 (70.5%) | 201 (79.1%) | 259 (86.6%) | < 0.001 |
LVEF left ventricular ejection fraction, BMI body mass index, PCI percutaneous coronary intervention, MI myocardial infarction, SBP systolic blood pressure, TIMI thrombolysis in myocardial infarction, IABP intra-aortic balloon pump, ACEIs angiotensin-converting enzyme inhibitors, ARBs angiotensin II receptor blockers